Phase II study of chidamide (CS055), a new subtype-selective oral histone deacetylase inhibitor, in patients with relapsed or refractory peripheral T-cell lymphoma.
Yuan-Kai Shi
No relevant relationships to disclose
Mei Dong
No relevant relationships to disclose
Xiao-Nan Hong
No relevant relationships to disclose
Wei-Jing Zhang
No relevant relationships to disclose
Ji-Feng Feng
No relevant relationships to disclose
Jun Zhu
No relevant relationships to disclose
Li Yu
No relevant relationships to disclose
Xiao-Yan Ke
No relevant relationships to disclose
Hui-Qiang Huang
No relevant relationships to disclose
Zhi-Xiang Shen
No relevant relationships to disclose
Yun Fan
No relevant relationships to disclose
Wei Li
No relevant relationships to disclose
Xie-Lan Zhao
No relevant relationships to disclose
Lu-Gui Qiu
No relevant relationships to disclose
He Huang
No relevant relationships to disclose